Ultragenyx Pharmaceutical Says FDA Grants Standard Full Approval Of FAYUVI For Treatment Of Pediatric Patients With Mucopolysaccharidosis Type IIIA

뉴스 본문을 불러오고 있어요.

Ultragenyx Pharmaceutical Says FDA Grants Standard Full Approval Of FAYUVI For Treatment Of Pediatric Patients With Mucopolysaccharidosis Type IIIA | 웨이프 WAPE

Ultragenyx Pharmaceutical Says FDA Grants Standard Full Approval Of FAYUVI For Treatment Of Pediatric Patients With Mucopolysaccharidosis Type IIIA

기사 요약

관련 종목

댓글 —